TY - JOUR
T1 - A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters
T2 - Sapporo athero-incretin study 1 (SAIS1)
AU - on behalf of SAIS Study Group
AU - Nomoto, Hiroshi
AU - Miyoshi, Hideaki
AU - Furumoto, Tomoo
AU - Oba, Koji
AU - Tsutsui, Hiroyuki
AU - Inoue, Atsushi
AU - Atsumi, Tatsuya
AU - Manda, Naoki
AU - Kurihara, Yoshio
AU - Aoki, Shin
AU - Takano, Y.
AU - Koyanagawa, N.
AU - Miyoshi, A.
AU - Yamamoto, K.
AU - Yamamoto, C.
AU - Nomoto, H.
AU - Tajima, N.
AU - Kameda, H.
AU - Cho, K. Y.
AU - Nakagaki, O.
AU - Nagai, S.
AU - Kondo, T.
AU - Miyoshi, H.
AU - Atsumi, T.
AU - Takashina, C.
AU - Watanabe, T.
AU - Ohira, H.
AU - Cho, K. Y.
AU - Nomoto, H.
AU - Endo, M.
AU - Kamoshima, H.
AU - Inoue, A.
AU - Ono, Y.
AU - Hagiwara, S.
AU - Misawa, K.
AU - Tsuchida, K.
AU - Manda, N.
AU - Kurihara, Y.
AU - Aoki, S.
AU - Perfield, James W.
N1 - Publisher Copyright:
© 2016 Nomoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - Objectives: The DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucosedependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride. Materials and Methods: In this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 -9.9 years with HbA1c levels of 7.5 -0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force1 Monitor), and serum metabolic markers were assessed before and after the treatment. Results: During the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.
AB - Objectives: The DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucosedependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride. Materials and Methods: In this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 -9.9 years with HbA1c levels of 7.5 -0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force1 Monitor), and serum metabolic markers were assessed before and after the treatment. Results: During the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different. Conclusions: Regardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.
UR - http://www.scopus.com/inward/record.url?scp=84991215222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991215222&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0164255
DO - 10.1371/journal.pone.0164255
M3 - Article
C2 - 27711199
AN - SCOPUS:84991215222
VL - 11
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 10
M1 - e0164255
ER -